Related Experiment Video

Updated: Apr 18, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K

Candidate tumor suppressor B-cell translocation gene 3 impedes neoplastic progression by suppression of AKT

Y-C Cheng1, P-H Chen1, H-Y Chiang1

  • 1Institute of Biomedical Sciences, Academia Sinica, 128 Section 2, Academia Road, Taipei 115, Taiwan.

Cell Death & Disease
|January 9, 2015
PubMed

Insights

B-cell translocation gene 3 (BTG3) suppresses AKT signaling, a key pathway in cancer. This discovery reveals a new tumor suppressor mechanism and a potential therapeutic peptide for cancer treatment.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Biochemistry

Background:

  • BTG3 (B-cell translocation gene 3) is a p53 target involved in growth regulation.
  • BTG3 is downregulated in human cancers, but its tumor suppressor role is unclear.
  • AKT signaling is frequently deregulated in various cancers.

Purpose of the Study:

  • To investigate the role of BTG3 as a tumor suppressor.
  • To elucidate the molecular mechanisms by which BTG3 regulates cancer cell growth.
  • To identify potential therapeutic strategies targeting the BTG3-AKT pathway.

Main Methods:

  • Investigated BTG3's interaction with AKT kinase.
  • Utilized BTG3 ablation and overexpression models in cell lines and mouse xenografts.
  • Analyzed downstream signaling pathways including GSK3β, β-catenin, and mesenchymal markers.
  • Identified and tested a BTG3-derived peptide for in vitro and cellular activity.

Main Results:

  • BTG3 directly binds and suppresses AKT kinase activity.
  • BTG3 ablation led to increased AKT activity, promoting cell migration and mesenchymal characteristics.
  • BTG3 overexpression inhibited tumor growth in vivo, correlating with reduced AKT phosphorylation and β-catenin levels.
  • A BTG3-derived peptide mimicked these tumor-suppressive effects.

Conclusions:

  • BTG3 acts as a tumor suppressor by inhibiting the AKT pathway.
  • This study uncovers a novel p53-downstream AKT inhibitory pathway.
  • A BTG3-derived peptide shows promise as a novel cancer therapeutic agent.

More Related Videos

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

9.2K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K